Hormonal
Tirzepatide, a dual GIP/GLP-1 receptor agonist administered once weekly, produces clinically meaningful weight loss (average 15-25% over 88 weeks) superior to placebo and semaglutide in adults with obesity or overweight.
If you have obesity or overweight with related health issues, Tirzepatide is an FDA-approved, once-weekly injection that works by mimicking gut hormones to reduce appetite and improve metabolism. Clinical trials show it leads to significant weight loss (up to 25% over nearly 2 years), often more than other popular drugs like semaglutide. It requires a calorie-restricted diet and exercise. Common side effects are gastrointestinal (nausea/diarrhea), but serious risks are rare. It is contraindicated for those with a history of medullary thyroid cancer.
Tirzepatide induced a weight loss of 25.3% from week 0 to week 88, compared to 9.9% for the placebo group... At all doses, Tirzepatide was both noninferior and superior and cause more significant reductions in body weight as compared to semaglutide
Why this rating
The paper cites multiple Phase 3 trials (SURPASS, SURMOUNT) and meta-analyses, though it is a narrative review rather than primary data.
Source
Tirzepaptide: A Promising Option for Treating Obesity and Overweight
Manoj Kumar Saurabh Amit · International Journal of Science and Research (IJSR) · 2024
DOI 10.21275/sr24305143919
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →